Replimune Group Inc Stock Research

Market Summary

USD25.89-0.24

Market Closed

-0.92%

REPL Stock Price

REPL RSI Chart

REPL Valuation

Market Cap

1.3B

Price/Earnings (Trailing)

-8.78

Price/Sales (Trailing)

417.83

Price/Free Cashflow

-11.64

REPL Price/Sales (Trailing)

REPL Profitability

Return on Equity

-38.2%

Return on Assets

-33.65%

Free Cashflow Yield

-8.59%

REPL Fundamentals

REPL Revenue

Revenue (TTM)

3.1M

Revenue Y/Y

-20.83%

Revenue Q/Q

-32.55%

REPL Earnings

Earnings (TTM)

-146.7M

Earnings Y/Y

-46.61%

Earnings Q/Q

-2.01%

Price Action

52 Week Range

13.0529.41

(Low)(High)

Last 7 days

-5.6%

Last 30 days

-3.4%

Last 90 days

43.3%

Trailing 12 Months

39.6%

REPL Financial Health

Current Ratio

16.12

REPL Investor Care

Buy Backs (1Y)

4.50%

Diluted EPS (TTM)

-2.74

Peers (Alternatives to Replimune Group)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
AMGN	135.3B	26.3B	-2.97%	16.81%	19.8	5.14	2.18%	21.86%
GILD	105.0B	27.1B	-0.99%	30.15%	31.49	3.87	-1.26%	-54.91%
MRNA	73.3B	21.4B	7.28%	27.41%	6.23	3.43	80.80%	66.62%
BIIB	41.9B	10.4B	5.85%	32.49%	14.62	4.04	-6.64%	85.32%
NBIX	10.4B	1.4B	-8.79%	49.41%	178.74	7.49	29.86%	-86.92%
MID-CAP
DNLI	3.9B	-	18.31%	0.06%	-12.88	32.03	-41.50%	-1123.42%
BEAM	3.2B	-	23.33%	-24.11%	-10.12	59.51	215916.67%	21.41%
SMALL-CAP
RCUS	1.7B	432.8M	17.41%	-21.00%	20.97	3.87	1042.97%	128.67%
BBIO	1.4B	-	35.16%	1.79%	-2.74	20.84	745.14%	12.80%
REPL	1.3B	3.1M	-3.43%	39.57%	-8.78	417.83	7.05%	-46.74%
NVAX	886.0M	1.8B	24.61%	-84.52%	-0.67	0.48	53.41%	-22.97%
FATE	574.9M	69.0M	-39.96%	-83.45%	-1.96	8.33	26.22%	-49.52%
SGMO	565.8M	112.1M	28.78%	-35.14%	-3.18	5.05	3.26%	1.99%
VXRT	142.4M	-	42.67%	-74.19%	-1.36	418.24	-71.03%	-64.56%
IBIO	6.7M	-	67.66%	-93.12%	-0.11	3.21	0.51%	-141.69%

Financials for Replimune Group

Income Statement (Last 12 Months)					(In Thousands)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Revenue	-4.7%	3,082	3,233	3,170	3,062	2,879
Operating Expenses	9.4%	144,141	131,809	118,314	108,510	99,087
S&GA Expenses	8.2%	44,740	41,340	38,769	34,476	30,084
R&D Expenses	9.9%	99,401	90,469	79,545	74,034	69,003
Interest Expenses	-100.0%	0	1.00	248	-	-
Net Income	-10.3%	-146,725.00	-133,023.00	-118,036.00	-107,884.00	-99,993.00
Net Income Margin	-15.7%	-47.61*	-41.13*	-37.22*	-35.22*	-
Free Cahsflow	-10.2%	-110,651.00	-100,434.00	-84,516.00	-77,705.00	-

* denotes actual numbers (not divided by Thousands)

Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Assets	-5.1%	436	459	461	485	503
Current Assets	-5.6%	379	402	404	428	444
Cash Equivalents	-20.8%	89	112	106	132	162
Net PPE	-4.3%	8	8	8	7	7
Liabilities	5.8%	52	49	50	48	46
Current Liabilities	15.9%	24	20	21	18	17
Shareholder's Equity	-6.4%	384	410	411	438	457
Retained Earnings	-12.2%	-396.60	-353.50	-311.20	-279.51	-249.83
Additional Paid-In Capital	1.9%	778	763	723	717	707
Shares Outstanding	0.9%	50	49	47	47	52
Float	-	620	-	-	-	-

* denotes actual numbers (not divided by Millions)

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Cashflow From Operations	-10.5%	-107.57	-97.32	-82.18	-75.75	-70.39
Share Based Compensation	2.7%	26	25	24	22	19
Cashflow From Investing	47.2%	-12.39	-23.48	-1.81	-123.75	-78.91
Cashflow From Financing	16.5%	44	38	7	7	265

Risks for REPL

What is the probability of a big loss on REPL?

95.4%

Probability that Replimune Group stock will be more than 20% underwater in next one year

94.1%

Probability that Replimune Group stock will be more than 30% underwater in next one year.

88.7%

Probability that Replimune Group stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does REPL drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Replimune Group was unfortunately bought at previous high price.

Drawdowns

Returns for REPL

Cumulative Returns on REPL

13.1%

3-Year Cumulative Returns

Which funds bought or sold REPL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-01-26	STRS OHIO	unchanged	-	42,000	116,000	-%
2023-01-24	Moody Aldrich Partners LLC	new	-	2,487,090	2,487,090	0.50%
2023-01-20	HARBOR CAPITAL ADVISORS, INC.	reduced	-2.11	259,059	736,059	0.71%
2023-01-13	Allworth Financial LP	unchanged	-	354	354	-%
2023-01-12	Hennion & Walsh Asset Management, Inc.	added	14.47	427,000	960,000	0.06%
2022-11-21	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	added	13.22	68,000	641,000	-%
2022-11-16	BNP PARIBAS ARBITRAGE, SNC	added	538.73	593,264	704,979	-%
2022-11-15	STATE STREET CORP	reduced	-12.11	-3,801,000	25,072,000	-%
2022-11-15	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
2022-11-15	ALLIANCEBERNSTEIN L.P.	unchanged	-	-6,000	532,000	-%

Latest Funds Activity

Are funds buying REPL calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own REPL

No. of Funds

Replimune Group News

Schedule 13G FIlings of Replimune Group

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Nov 18, 2022	redmile group, llc	9.9%	5,165,131	SC 13G/A
Sep 14, 2022	atlas venture fund x, l.p.	4.4%	2,164,037	SC 13D/A
Feb 14, 2022	redmile group, llc	9.9%	4,775,461	SC 13G/A
Feb 14, 2022	omega fund iv, l.p.	10.6%	5,012,052	SC 13G/A
Feb 14, 2022	price t rowe associates inc /md/	12.5%	5,868,638	SC 13G/A
Feb 09, 2022	fmr llc	-	0	SC 13G/A
Jul 12, 2021	price t rowe associates inc /md/	10.8%	5,069,450	SC 13G/A
Feb 16, 2021	bain capital life sciences fund, l.p.	0%	0	SC 13G/A
Feb 16, 2021	price t rowe associates inc /md/	5.7%	2,625,691	SC 13G
Feb 16, 2021	forbion capital fund iii cooperatief u.a.	11.13%	5,115,121	SC 13G/A

REPL Fair Value

Recent SEC filings of Replimune Group

View All Filings

Date Filed	Form Type	Document
Jan 04, 2023	8-K	Current Report
Dec 13, 2022	4	Insider Trading
Dec 12, 2022	424B5	Prospectus Filed
Dec 12, 2022	8-K	Current Report
Dec 07, 2022	8-K	Current Report
Dec 07, 2022	424B5	Prospectus Filed
Dec 06, 2022	SC 13D/A	13D - Major Acquisition
Dec 05, 2022	3	Insider Trading
Dec 05, 2022	4	Insider Trading
Nov 18, 2022	SC 13G/A	Major Ownership Report

Latest Insider Trading transactions for REPL

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2022-12-09	Esposito Pamela	acquired	15,150	1.01	15,000	chief business officer
2022-12-09	Esposito Pamela	sold	-375,450	25.03	-15,000	chief business officer
2022-12-01	Xynos Konstantinos	acquired	-	-	17,500	chief medical officer
2022-05-16	Patel Sushil	sold	-155,923	14.59	-10,687	chief commercial officer
2022-05-16	Esposito Pamela	sold	-51,167.1	14.59	-3,507	chief business officer
2022-05-16	Love Colin	sold	-92,267.2	14.59	-6,324	chief operating officer
2022-05-16	Lewis Tanya	sold	-79,851.1	14.59	-5,473	chief dev. op officer
2022-05-16	Coffin Robert	sold	-83,702.8	14.59	-5,737	president & chief r&d officer
2022-05-16	Astley-Sparke Philip	sold	-140,531	14.59	-9,632	chief executive officer
2022-05-16	Franchi Jean M.	sold	-50,131.2	14.59	-3,436	chief financial officer

About Replimune Group

Philip Astley-Sparke

www.replimune.com/

150

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

REPL Income Statement

2022-09-30

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating expenses:
Research and development	$ 28,834	$ 19,902	$ 58,312	$ 38,456
Selling, general and administrative	12,745	9,345	24,143	18,172
Total operating expenses	41,579	29,247	82,455	56,628
Loss from operations	(41,579)	(29,247)	(82,455)	(56,628)
Other income (expense):
Research and development incentives	574	725	1,425	1,513
Investment income	1,112	80	1,455	172
Interest expense on finance lease liability	(550)	(557)	(1,102)	(1,115)
Other (expense) income	(2,659)	(356)	(4,678)	(608)
Total other (expense) income, net	(1,523)	(108)	(2,900)	(38)
Net loss	$ (43,102)	$ (29,355)	$ (85,355)	$ (56,666)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.79)	$ (0.56)	$ (1.57)	$ (1.09)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.79)	$ (0.56)	$ (1.57)	$ (1.09)
Weighted average common shares outstanding, basic (in shares)	54,770,291	52,081,325	54,492,395	51,962,795
Weighted average common shares outstanding, diluted (in shares)	54,770,291	52,081,325	54,492,395	51,962,795

REPL Balance Sheet

2022-09-30

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2022	Mar. 31, 2022
Current assets:
Cash and cash equivalents	$ 88,930	$ 105,948
Short-term investments	282,890	289,707
Research and development incentives receivable	2,589	3,055
Prepaid expenses and other current assets	4,981	5,267
Total current assets	379,390	403,977
Property, plant and equipment, net	7,910	7,933
Research and development incentives receivable, non-current	1,296	0
Restricted cash	1,636	1,636
Right-to-use asset - operating leases	4,984	5,552
Right-to-use asset - financing leases	40,879	42,094
Total assets	436,095	461,192
Current liabilities:
Accounts payable	3,996	3,732
Accrued expenses and other current liabilities	15,939	13,392
Operating lease liabilities, current	1,002	1,070
Financing lease liabilities, current	2,600	2,562
Total current liabilities	23,537	20,756
Operating lease liabilities, non-current	4,280	4,801
Financing lease liabilities, non-current	24,206	24,406
Total liabilities	52,023	49,963
Commitments and contingencies (Note 11)
Stockholders' equity
Common stock, $0.001 par value; 150,000,000 shares authorized as of September 30, 2022 and March 31, 2022; 49,739,407 and 47,338,660 shares issued and outstanding as of September 30, 2022 and March 31, 2022, respectively	50	47
Additional paid-in capital	777,650	723,359
Accumulated deficit	(396,559)	(311,204)
Accumulated other comprehensive income (loss)	2,931	(973)
Total stockholders' equity	384,072	411,229
Total liabilities and stockholders' equity	$ 436,095	$ 461,192